| Cover | Sep. 20, 2024 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Sep. 20, 2024 |
| Entity File Number | 001-42275 |
| Entity Registrant Name | Kairos Pharma, Ltd. |
| Entity Central Index Key | 0001962011 |
| Entity Tax Identification Number | 46-2993314 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 2355 Westwood Blvd |
| Entity Address, Address Line Two | #139 |
| Entity Address, City or Town | Los Angeles |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 90064 |
| City Area Code | (310) |
| Local Phone Number | 948-2356 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.001, per share |
| Trading Symbol | KAPA |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
